Efficacy of in-class interleukin-23 inhibitor switching: risankizumab following guselkumab failure in moderate-to-severe psoriasis treatment

Br J Dermatol. 2021 Mar;184(3):559-561. doi: 10.1111/bjd.19575. Epub 2020 Nov 12.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Humans
  • Interleukin-23*
  • Psoriasis* / drug therapy
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Interleukin-23
  • guselkumab
  • risankizumab